Regorafenib Post-marketing Surveillance in Japan

Drug Use Investigation of Regorafenib/ STIVARGA for Gastrointestinal Stromal Tumor Progressed After Cancer Chemotherapy

The objective of this study is to assess safety and effectiveness of Regorafenib using in real clinical practice

This study is a regulatory post-marketing surveillance in Japan, and it is a local prospective and observational study of patients who have received Regorafenib for gastrointestinal stromal tumors progressed after cancer chemotherapy.

A total of 135 patients are to be enrolled and assessed in 6 months standard observational period. At 12 months and 24 months after the first administration of Regorafenib for confirmation of efficacy information including treatment duration and survival status of the patient.

Inclusion Criteria:

• Patients who are treated with Regorafenib/ STIVARGA and meet the product label.

Exclusion Criteria:

• Patients who are treated with Regorafenib/ STIVARGA and don't meet the product label.